Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study

Author:Boer, Ibolya   Cree, Bruce   Wiendl, Heinz   Cross, Anne   Delgado, Sylvia   Habek, Mario   Khachanova, Natalia   Ward, Brian   Totolyan, Natalia   Mancione, Linda   Sullivan, Roseanne   Zielman, Ronald   Hu, Xixi   Das Gupta, Ayan   Montalban, Xavier   Winthrop, Kevin   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.010  

Author Institution:Novartis Pharma AG, Basel, Switzerland  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Washington University School of Medicine, Saint Louis, MO  University of Miami Miller School of Medicine, Miami, FL  University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia  Pirogov Russian National Research Medical University, Moscow, Russian Federation  Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada  First Saint Petersburg State Medical University, St Petersburg , Russian Federation  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V, Amsterdam, Netherlands  Novartis Healthcare Private Limited, Hyderabad, India  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  School of Public Health at Oregon Health & Science University, Portland, OR  

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis

Author:Bar-Or, Amit   Wiendl, Heinz   De Seze, Jerome   Correale, Jorge   Cross, Anne   Derfuss, Tobias   Selmaj, Krzysztof   Winthrop, Kevin   Giacomini, Paul   Sacca, Francesco   Hu, Xixi   Sullivan, Roseanne   Jehl, Valentine   Boer, Ibolya   Bhatt, Alit   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.007  

Author Institution:Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  University of Muenster, Muenster, Germany  University Hospital of Strasbourg, Strasbourg, France  Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina  Washington University School of Medicine, Clayton, MO  Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland  Center for Neurology, Lodz, Lodz, Poland  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare Pvt. Ltd., Hyderabad, India  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA  

Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years

Author:Wiendl, Heinz   Hauser, Stephen   Nicholas, Jacqueline   De Seze, Jerome   Meuth, Sven   Giacomini, Paul   Robertson, Derrick   Wray, Sibyl   Bhatt, Alit   Hu, Xixi   Fu, Haoyi   Jehl, Valentine   Sullivan, Roseanne   Boer, Ibolya   Cohen, Jeffrey   Kappos, Ludwig   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.010  

Author Institution:University of Münster, Münster, Germany, Muenster, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, United States, San Francisco, CA  OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  Hope Neurology MS Center, Knoxville, TN, USA, Knoxville, TN  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma A.G. Basel, Switzerland, Basel, Switzerland  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland